Quality assurance study of bacterial antigen testing of cerebrospinal fluid. by Kiska, Deanna L. et al.
JOURNAL OF CLINICAL MICROBIOLOGY, May 1995, p. 1141–1144 Vol. 33, No. 5
0095-1137/95/$04.0010
Copyright q 1995, American Society for Microbiology
Quality Assurance Study of Bacterial Antigen Testing
of Cerebrospinal Fluid
DEANNA L. KISKA,1 MELISSA C. JONES,1 MARY ELLEN MANGUM,1
DEBORAH ORKISZEWSKI,1 AND PETER H. GILLIGAN1,2*
Clinical Microbiology and Immunology Laboratories, University of North Carolina Hospitals,1 and
Departments of Microbiology-Immunology and Pathology, University of North Carolina
School of Medicine,2 Chapel Hill, North Carolina 27514
Received 17 October 1994/Returned for modification 1 December 1994/Accepted 2 February 1995
Bacterial antigen testing (BAT) of cerebrospinal fluid (CSF) by latex agglutination is a low-yield procedure
in patients whose CSF specimens have normal laboratory parameters. Between August 1992 and August 1994,
we evaluated 287 bacterial antigen (BA) test requests to determine whether yields could be improved and
whether patient costs could be reduced by canceling BAT for those patients with normal CSF parameters (cell
count, protein, glucose) after consultation with physicians. A total of 171 (68%) BA tests were canceled by this
approach. None of these CSF specimens was culture positive for an organism detectable by BAT. Of the
remaining 116 CSF specimens tested, only 3 were positive by BAT, one each for Neisseria meningitidis,
Streptococcus pneumoniae, and group B streptococcus. Only 43 of the CSF specimens tested had at least two
abnormal parameters; the 3 positive CSF specimens were included in this group. In light of the low rate of
positivity, the number of BA tests can be further reduced by establishing criteria that must be met before a CSF
specimen is accepted for BAT. After review of our data and the literature concerning this topic, we concluded
that only specimens with leukocyte counts of $50 cells per mm3 should be tested. Of 287 specimens evaluated
in our study, only 36 met this criterion, including the 3 BA-positive specimens. Enacting such a restriction
would have reduced the total number of BA tests by 251 (87%) without compromising patient care. A laboratory
cost savings of $6,500 per year would have been realized, with a substantial reduction in the cost per positive
test. Patient charges would have been reduced by $12,500 per year.
In the early 1970s, immunodiagnostic methods for the de-
tection of bacterial antigens (BAs) in cerebrospinal fluid (CSF)
emerged to fill the need for prompt identification of common
agents of bacterial meningitis (5, 11, 31). Numerous assays and
commercial kits, including counterimmunoelectrophoresis, co-
agglutination, and latex particle agglutination, were rapidly
developed to serve as adjuncts to routine culture and Gram
staining (3, 8, 9, 17). During this era, chloramphenicol was
used as empiric therapy for meningitis to ensure adequate
coverage against b-lactamase-producing Haemophilus influen-
zae type b. Because of the toxicity associated with chloram-
phenicol use in children, bacterial antigen testing (BAT) was
deemed particularly important in this setting to detect H. in-
fluenzae meningitis. A negative BA test for H. influenzae in
CSF would, in many cases, lead to the early discontinuation of
chloramphenicol.
In recent years, BAT has been dramatically affected by
changes in infectious disease epidemiology and improvements
in therapeutics. The value of BAT for detecting H. influenzae
type b in CSF must now be called into question for these
reasons. The extended-spectrum cephalosporins ceftriaxone
and cefotaxime have been shown to be reliable therapeutic
agents for empirically treating meningitis caused by H. influ-
enzae, Streptococcus pneumoniae, and Neisseria meningitidis,
thus making detection of these pathogens by BAT somewhat
less important. More significantly, the widespread use of the
conjugate H. influenzae type b vaccine has resulted in a sub-
stantial decline in the incidence of invasive H. influenzae dis-
ease. Over the past 22 months, no cases of invasive H. influ-
enzae disease have been seen at our institution.
Although BAT has been used for more than a decade, much
controversy has arisen over the proper use of this test. BAT
was originally designed to be used in patients who demon-
strated laboratory and clinical findings consistent with menin-
gitis (3, 5, 8, 11). Despite these initial intentions, this test has
been used much too often as a screening tool in cases of
suspected meningitis in patients whose CSF specimens have
normal chemistries and cell counts. The indiscriminate use of
BAT without consideration of the chemical and cytological
profiles of the CSF is a misuse of valuable resources.
In view of the present emphasis in the health care commu-
nity on the cost-effective use of laboratory services and the
changing epidemiology of bacterial meningitis, we felt that it
was prudent to formulate a policy concerning the judicious use
of BAT. We prospectively evaluated 287 BA test requests over
a 2-year period in an effort to determine whether unnecessary
testing could be reduced by recommending to physicians that
the test be canceled if the CSF analysis was normal. We also
determined whether certain CSF parameters would be reliable
predictors of BA test positivity and, thus, would allow us to
limit our testing to such specimens.
MATERIALS AND METHODS
Study design. We prospectively studied the use of BAT of CSF in our insti-
tution from August 1992 to August 1994. All CSF specimens submitted to our
laboratory for BAT were included in the study if the following CSF tests were
done: protein, glucose, cell count, Gram staining, and bacterial culture. In order
to reduce the number of unnecessary BA tests, we consulted the ordering phy-
sician and recommended that BAT be canceled if no abnormal CSF parameters
(protein, glucose, cell count) were noted or if only one abnormal parameter was
present. Normal values for these parameters at our institution are as follows:
leukocyte (WBC) count, 0 to 5 cells per mm3; protein concentration, 15 to 45
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mg/dl; and glucose concentration, 50 to 75 mg/dl. During this initial phase of the
study, age-related variations in protein concentrations and cell counts were not
taken into account in determining when to call a physician concerning cancella-
tion of the test. If the physician insisted that BAT be done, despite normal CSF
parameters, he or she was asked to provide a brief explanation as to why such
testing was deemed necessary. Upon completion of the study, the data were
analyzed to determine if a further reduction in BAT could be achieved by
establishing which CSF parameter(s) was indicative of bacterial meningitis and
predictive of a positive antigen test. In this final analysis, age-related variations
in protein concentrations and cell counts were taken into consideration in de-
termining whether the parameter was abnormal. WBC counts also were adjusted
on the basis of the number of erythrocytes in the CSF in instances of traumatic
lumbar tap. One WBC per 700 erythrocytes was subtracted from the total WBC
count in the CSF (4).
BAT. BAT was done with the Directigen meningitis combo panel (Becton
Dickinson Microbiology Systems, Cockeysville, Md.) according to the manufac-
turer’s recommendations. Capsular polysaccharide antigens detected by this kit
include those from H. influenzae type b, S. pneumoniae (84 serotypes), N. men-
ingitidis A, B, C, Y, and W135, group B streptococci, and Escherichia coli K1.
Bacterial culture. All CSF specimens were inoculated either directly or after
centrifugation onto chocolate agar and 5% sheep blood agar and into thiogly-
colate broth. The agar plates were incubated for 4 days at 358C in 5% CO2 and
were examined daily for growth. The thioglycolate broth was incubated under the
same conditions for 7 days and was examined daily for growth.
RESULTS
Between August 1992 and August 1994, 303 CSF specimens
were submitted to the Clinical Microbiology Laboratory for
BAT. Sixteen of these specimens were excluded from the study
because of a lack of a complete CSF analysis or bacterial
culture. Two hundred thirty (80%) of the 287 CSF specimens
included in the study exhibited either normal values for CSF
protein, glucose, and cell count or one abnormal parameter
(Table 1). Consultation with physicians concerning the 230
specimens resulted in cancellation of 157 of the requested BA
tests. The remaining 73 specimens were processed at the in-
sistence of physicians, and all were negative by BAT, Gram
staining, and culture. The most frequent reason (59%) given to
justify the testing of normal CSF specimens was the adminis-
tration of antimicrobial therapy for some period of time prior
to the lumbar puncture. Thirteen (18%) of the 73 specimens
were tested because of insistence by physicians, although an
explanation was never given as to why it was necessary to run
the test. Other reasons given for performing the test included
altered mental status or meningeal signs (8%) and immuno-
suppression (4%).
Fifty-seven (20%) of the 287 CSF specimens included in the
study demonstrated at least two abnormal parameters (Table
1). Fourteen of these 57 requested BA tests were canceled by
physicians. Of the 43 abnormal specimens tested by BAT, 3
were positive. Two patients with positive BA tests subsequently
had positive CSF cultures for the organisms detected by BAT
(Table 2). A third patient, with a positive BA test for S. pneu-
moniae, had a negative CSF culture. This patient had a positive
blood culture for S. pneumoniae prior to transfer to our insti-
tution. No specimens were positive for H. influenzae type b by
BAT or CSF culture. The 3 CSF specimens which were positive
for BA represented 3% of the 116 CSF specimens tested by
BAT. The total number of BA tests reduced by physician
consultation was 171 (68%). At a charge to the patient of $100
for BAT, this represented a savings of $8,550 per year (Table
3). Laboratory costs for performing BAT were reduced by
$4,400 per year.
DISCUSSION
In the current era of health care reform, many laboratories
are critically evaluating the type of tests which are currently
available and how to apply those tests to achieve clinically
significant and cost-effective results. There is a movement to-
ward limiting or discontinuing those tests which are unlikely to
affect clinical decisions concerning patient care. BAT was ini-
tially designed to detect bacterial pathogens in the CSF of
patients with clinical and laboratory findings consistent with
meningeal infection and especially in those patients who had
received antimicrobial therapy prior to lumbar puncture. Too
frequently, physicians order BA tests as part of a battery of
tests done on all patients from whom CSF is obtained. By
failing to define the specific population in whom BAT may be
of some value, i.e., those patients with evidence of meningitis,
the rate of positivity of the test is exceedingly low. In our
hospital population, only 3% of BA tests were positive. Others
have found similarly low rates (2, 24, 26). Additionally, results
from several studies have shown that positive BA test results
rarely affect patient therapy (16, 24, 26). The low rate of pos-
itivity of this test as well as its minimal impact on patient care
necessitate that the use of this test be reevaluated. Some would
argue that in view of changes in the epidemiology of bacterial
meningitis because of widespread H. influenzae type b vacci-
nation, BAT is no longer of any clinical utility. Our position is
that BAT continues to be of value but only if it is used appro-
priately.
Proposals have been made to perform laboratory testing on
TABLE 1. Comparison of findings for CSF specimens








Not tested Tested BA positive
0–1 230 157 73 0
2–3 57 14 43 3
Total 287 171 116 3
a Cell count, glucose concentration, and/or protein concentration.
TABLE 2. Characteristics of patients with positive BA results
Patient characteristic Patient 1 Patient 2 Patient 3
Age (yr) 80 36 15
Glucose concn (mg/dl) 6 47 7
Protein concn (mg/dl) 1,358 147 180
Cell count (% PMNsa) 21,525 (96) 2,300 (87) 1,850 (86)






Culture result Negative Rare group B strep Few N. meningitidis
Antigen result S. pneumoniae Group B streptococci N. meningitidis C, W135
Previous antibiotic treatment Yes Yes No
a PMNs, polymorphonuclear cells.
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CSF in a logical sequence, relying on standard tests such as cell
count, differential, protein and glucose concentrations, and
Gram staining to guide the decision to order additional testing
(10, 19, 25, 27, 29). The cell count and differential in CSF have
been shown to be sensitive indicators of bacterial meningitis,
more so than glucose and protein concentration estimations,
which are often nonspecific and of limited diagnostic value (13,
19, 29, 34–36). Using a WBC count of $50 cells per mm3 as a
criterion for performing BAT, Werner and Kruger (36)
achieved 100% sensitivity in predicting BA-positive specimens
(36). Others have used both higher and lower cell counts with
similar results (7, 29). In applying any biochemical or cytologic
criterion for screening CSF, there is always the argument that
immunosuppression or prior antibiotic therapy will alter the
CSF picture. Clearly, immunosuppression can affect the cell
count in CSF. Fishbein et al. (14) found that 6% of patients
with meningitis seen over a 13-year period demonstrated an
absence of CSF pleocytosis (,6 cells per mm3). All of these
patients had underlying conditions which were considered to
contribute to a decreased immune response. Therefore, one
must be cautious in applying any CSF screening procedure to
such patients.
The effect of prior antimicrobial therapy on the CSF tends
not to be as clear-cut as that of immunosuppression. Many of
the normal CSF specimens that we tested for BA were tested
at the insistence of physicians who were concerned that prior
therapy had altered the bacterial picture of the CSF. In re-
viewing the literature, we were not convinced that prior ther-
apy so drastically altered the cell count in CSF that it could not
be used as a criterion for testing. In many pediatric patients
with meningitis, prior therapy typically consists of antibiotics
administered orally for otitis media, usually within 1 week of
hospital admission. These partially treated patients may have a
decreased likelihood of a positive CSF culture or Gram stain
result, but the therapy has minimal effect on CSF parameters
such as cell count (4, 6, 12, 15, 18, 20–23, 25, 28, 30, 32, 33, 35,
36). Even after institution of appropriate therapy for menin-
gitis, the CSF picture can remain abnormal for 48 to 72 h (1).
Persistent pleocytosis (.60 cells per mm3) has been observed
after 7 days of therapy in 50% of children treated for bacterial
meningitis (4). With this information in mind, we sought to
establish a criterion based on the cell count in CSF as a means
of eliminating unnecessary BAT.
In reviewing numerous studies addressing various durations
and types of antibiotic pretreatment, the cell count in CSF
remained $50 cells per mm3 in almost every clinical setting
and was typically much higher (6, 12, 20–23, 28, 30, 32, 36).
Therefore, we chose to adopt a cell count of$50 cells per mm3
to distinguish those specimens most likely to be positive by
BAT. Of a total of 287 specimens in the study, only 36 met this
criterion, including the 3 specimens positive by BAT (Table 3).
Enacting this cell count restriction would have resulted in a
patient cost savings of $25,100 ($12,550/year) on the basis of a
charge of $100 per test. Laboratory costs would have been
reduced by $13,000 ($6,500/year). The cost for finding a posi-
tive test would drop from $2,000 to $620. We plan to institute
this criterion on all future CSF specimens received in our
laboratory for BAT, including those from patients who have
received antibiotic therapy. CSF specimens from immunosup-
pressed patients, identified by physician consultation, will not
be subject to this restriction.
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